A recent meta-analysis reports that cinacalcet hydrochloride has no significant effect on all-cause and cardiovascular mortality in dialysis patients with secondary hyperparathyroidism. However, these findings must be interpreted with caution, given the limitations of the trials included in the meta-analysis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Block, G. A. et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N. Engl. J. Med. 350, 1516–1525 (2004).
Komaba, H. et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 5, 2305–2314 (2010).
Lopez, I. et al. Calcimimetic R-568 decreases extraosseous calcifications in uremic rats treated with calcitriol. J. Am. Soc. Nephrol. 17, 795–804 (2006).
Raggi, P. et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol. Dial. Transplant. 26, 1327–1339 (2011).
Cunningham, J. et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 68, 1793–1800 (2005).
Block, G. A. et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int. 78, 578–589 (2010).
Palmer, S. C. et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med. 10, e1001436 (2013).
The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. 367, 2482–2494 (2012).
LeLorier, J. et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N. Engl. J. Med. 337, 536–542 (1997).
Komaba, H. et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. Am. J. Kidney Dis. 60, 262–271 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H. Komaba has received honoraria from Kyowa Hakko Kirin and Chugai Pharmaceutical.
M. Fukagawa has acted as a consultant for Kyowa Hakko Kirin, Bayer Yakuhin, and Novartis; has received honoraria from Kyowa Hakko Kirin, Chugai Pharmaceutical, Bayer Yakuhin, Novartis, Genzyme, and Abbott Japan; and has received grants/research support from Kyowa Hakko Kirin, Chugai Pharmaceutical, and Bayer Yakuhin.
Rights and permissions
About this article
Cite this article
Komaba, H., Fukagawa, M. Effect of cinacalcet on survival—the saga continues. Nat Rev Nephrol 9, 435–436 (2013). https://doi.org/10.1038/nrneph.2013.130
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2013.130
